^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RC118

    i
    Other names: RC118, RC118-ADC, YH005 ADC, RC-118, RC 118
    Associations

    News

    Trials
    Company:
    Biocytogen, Rongchang Pharma
    Drug class:
    Microtubule inhibitor, CLDN18.2-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    9ms
    A Study of RC118 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=135, Recruiting, RemeGen Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Sep 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN1 positive
    |
    RC118
    1year
    A Study of RC118 Plus Toripalimab in Patients With Locally Advanced Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=64, Recruiting, RemeGen Co., Ltd.
    New P1/2 trial • Combination therapy • IO biomarker • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN1 positive
    |
    Loqtorzi (toripalimab-tpzi) • RC118
    over1year
    A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=7, Completed, RemeGen Co., Ltd. | Active, not recruiting --> Completed | N=33 --> 7 | Trial primary completion date: Apr 2023 --> Nov 2022
    Trial completion • Enrollment change • Trial primary completion date • Metastases
    |
    CLDN18 (Claudin 18)
    |
    RC118
    2years
    A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, RemeGen Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    CLDN18 (Claudin 18)
    |
    RC118
    over2years
    A Study of RC118 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=135, Recruiting, RemeGen Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLDN18 (Claudin 18)
    |
    RC118
    almost3years
    A Study of RC118 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=135, Not yet recruiting, RemeGen Co., Ltd.
    New P1/2 trial
    |
    CLDN18 (Claudin 18)
    |
    RC118
    almost3years
    A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=33, Recruiting, RemeGen Co., Ltd. | Trial completion date: Feb 2022 --> May 2023 | Trial primary completion date: Dec 2021 --> Apr 2023
    Trial completion date • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    RC118
    3years
    A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=33, Recruiting, RemeGen Co., Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    CLDN18 (Claudin 18)
    |
    RC118
    over3years
    A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=33, Not yet recruiting, RemeGen Co., Ltd.
    Clinical • New P1 trial
    |
    CLDN18 (Claudin 18)
    |
    RC118